Johnson & Johnson (Auris Health)

by Johnson & Johnson (Auris Health)  · Based in United States → — Pioneering the next era of medical intervention by developing platforms that enhance physician capabilities, evolve minimally invasive techniques, and create new categories of care that redefine optimal patient outcomes.
Interventional Radiology Oncology Pulmonology

Regulatory Status Disclosed

Overview

The Johnson & Johnson (Auris Health) Monarch Platform is a medical AI tool that integrates robotics, software, data science, and endoscopy to assist physicians in diagnostic and therapeutic bronchoscopic procedures. It is primarily designed to enable earlier and more accurate diagnosis of small, hard-to-reach nodules in the periphery of the lung, which are often indicative of lung cancer.

  • What it does: The Monarch Platform allows physicians to navigate a flexible robotic endoscope into the lungs with improved reach, vision, and control. It combines traditional endoscopic views with computer-assisted navigation based on 3D models of the patient’s lung anatomy, providing continuous bronchoscope vision throughout the procedure. The system facilitates obtaining tissue samples for biopsy from peripheral lung nodules.
  • Who it is for: This tool is for pulmonologists and other specialists involved in the diagnosis and treatment of lung conditions, particularly lung cancer. It is utilized in care settings such as hospitals and endoscopy suites for outpatient procedures. The Monarch Platform has also received clearance for use in urology for kidney stone removal procedures, making it a multispecialty robotic solution.
  • How it fits a clinical or practice workflow: Physicians use a controller-like interface to guide the bronchoscope. Pre-procedural planning involves generating virtual 3D reconstructions from CT scans and mapping potential pathways to the target nodule. During the procedure, real-time visualization and electromagnetic navigation provide a roadmap to the nodule. The system’s stability and precision aid in reaching deep lung nodules and safely taking tissue samples without incision.
  • Notable capabilities: The Monarch Platform offers improved access to peripheral lung nodules that may be difficult to reach with conventional bronchoscopy. It integrates AI features for pre-procedural planning, including automatically generating more accurate nodule boundaries. The system also supports continuous bronchoscope vision and computer-assisted navigation.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Robotic-assisted bronchoscopy
  • Advanced navigation and visualization
  • 3D mapping of lung anatomy
  • Precision targeting of peripheral lung nodules
  • Flexible robotic endoscope
  • Minimally invasive access

Use Cases

  • Biopsy of peripheral lung nodules
  • Diagnostic evaluation of lung lesions
  • Therapeutic interventions in the lung
  • Early detection of lung cancer

What Physicians Need to Know

Evidence Base
The Monarch Platform integrates robotics, micro-instrumentation, endoscope design, sensing, and data science. It combines computer-assisted navigation based on 3D models of the patient's lung anatomy with traditional endoscopic views. The system is designed to help physicians diagnose lung nodules when they are small and more easily treated. Auris Health is committed to building robust clinical evidence to support the Monarch Platform's use in interventional pulmonology.
Clinical Validation Studies
The BENEFIT study, a prospective, multicenter study, evaluated the safety and feasibility of the Monarch Platform for diagnostic and therapeutic bronchoscopic procedures. Early results from the first-in-human study showed the system localized lesions in 92% of cases among 24 patients, with no significant adverse events. Later data from 54 patients demonstrated successful localization in 96.3% of procedures. The overall diagnostic yield in the BENEFIT study was 74.1%, and 70% for lung nodules outside the airway, which compares favorably to 30-40% for non-robotic technology. The study reported pneumothorax in 3.7% of procedures, with chest tube placement required in 1.9%. The TARGET trial, a prospective multicenter study, was launched in December 2019 to further characterize the safety and efficacy of the Monarch Platform. Previous studies (REACH and ACCESS) demonstrated improved reach and high accuracy in cadaveric lungs.
Differential Diagnosis Support
The Monarch Platform is specifically designed to aid in the diagnosis of peripheral pulmonary lesions, particularly small and hard-to-reach lung nodules, which are critical for early lung cancer detection. The system provides continuous bronchoscope vision throughout the procedure, enabling physicians to biopsy difficult-to-reach nodules.
Clinical Workflow Integration
The Monarch Platform utilizes a familiar controller-like interface, similar to a video game controller, for intuitive navigation of the flexible robotic endoscope. It is designed to integrate into real clinic workflows. The system aims to enhance physician capabilities and evolve minimally invasive techniques. Over 1,000 bronchoscopic procedures using the Monarch Platform were performed by August 2019.
Physician Tip

The Monarch Platform offers enhanced precision and control for navigating to and biopsying hard-to-reach lung nodules, potentially leading to earlier and more accurate lung cancer diagnoses. Familiarity with a controller-like interface can make the robotic system intuitive to operate. The continuous vision and computer-assisted navigation provided by the platform can improve confidence in reaching targeted lesions.

Auris Health, as part of Johnson & Johnson Medical Devices Companies, contributes to J&J's broader strategy in digital surgery, complementing other robotic platform technologies in development for general surgery (Verb Surgical) and orthopaedics (Orthotaxy). The Monarch Platform is designed to integrate robotics, micro-instrumentation, endoscope design, sensing, and data science. While the primary focus is on lung cancer, future endoscopic clinical indications are envisioned. The system is designed to fit into existing clinical workflows.

Details

Category Clinical Decision Support & Reference, Radiology & Imaging AI
Pricing Unknown
Compliance
BAA AvailableUnknown
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
SOC 2 Yes AI-estimated
GDPR Yes AI-estimated
Integrations
EHR Not specified
Specialties Interventional Radiology, Oncology, Pulmonology, Thoracic Surgery

Support & Reliability

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Johnson & Johnson (Auris Health)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Johnson & Johnson (Auris Health).

Loading videos...

View all on YouTube

Frequently Asked Questions

Auris Health's Monarch Platform is primarily indicated for bronchoscopy procedures, particularly for the diagnosis and treatment of small, peripheral lung nodules. It integrates with clinical decision support by providing enhanced visualization, navigation, and procedural control, aiming to improve diagnostic yield and treatment precision.
The learning curve for the Monarch Platform varies among physicians but is generally supported by comprehensive training programs offered by Johnson & Johnson. These programs include hands-on training, simulation, and proctoring to help ensure physicians achieve proficiency and adhere to best practices for optimal patient outcomes.
Studies suggest that robotic bronchoscopy with the Monarch Platform offers improved diagnostic yield for peripheral lung nodules compared to conventional bronchoscopy, due to its enhanced maneuverability and precision. It aims to provide a safer alternative to CT-guided biopsy by reducing the risk of pneumothorax and hemorrhage, though comparative efficacy can depend on nodule characteristics and physician experience.
The cost implications of integrating Auris Health technology involve the initial capital investment for the Monarch Platform, along with ongoing costs for maintenance and disposable instruments. While specific pricing models are proprietary, institutions often evaluate the long-term cost-effectiveness based on improved diagnostic yield, reduced complications, and potential for earlier intervention compared to alternative, often more invasive, procedures.
While generally safe, limitations of the Monarch Platform can include its applicability to extremely small or difficult-to-access nodules, and the need for specialized training. Contraindications are typically similar to those for conventional bronchoscopy, such as severe coagulopathy or unstable cardiac conditions. Its use might require additional precautions in patients with compromised respiratory function or those who cannot tolerate prolonged procedures.
Long-term data on patient outcomes and recurrence rates following interventions with the Monarch Platform are continually being gathered through ongoing clinical studies and post-market surveillance. Initial studies have focused on diagnostic yield and immediate procedural safety, with a growing body of evidence emerging regarding long-term efficacy in managing lung nodules and potentially reducing recurrence through more precise diagnosis and treatment.

Related Tools

Stanford University
Stanford University
Clinical Decision Support & Reference
Stanford Online's "AI in Healthcare" program provides a comprehensive overview of artificial intelligence's applications and implications within the medical field.
RADIN Health
RADIN Health
Clinical Decision Support & Reference
RADINA is an AI-powered platform by RADIN Health designed to optimize radiology workflows, enhance diagnostic accuracy, and streamline reporting.
Med-PaLM 2
Google
Clinical Decision Support & Reference
Med-PaLM 2 is a large language model from Google, fine-tuned for healthcare to provide high-quality answers to medical questions and support clinical decision-making.
Pacmed Critical Discharge
Pacmed
Clinical Decision Support & Reference
Pacmed Critical Discharge is an AI tool that predicts the probability of death or readmission within seven days of ICU discharge, providing explainable insights for physicians.
AiZtech Labs
AiZtech Labs
Clinical Decision Support & Reference
AiZtech Labs provides enterprise-grade AI solutions for healthcare, focusing on operational efficiency, diagnostic accuracy, and patient care workflows for providers and health systems.
Stethophone Pro
Sparrow Acoustics
Cardiology AI
Stethophone Pro transforms smartphones into advanced cardiac screening tools, enabling clinicians to capture, interpret, and visualize heart sounds for early detection of cardiovascular diseases.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-08-24 | First Added: 2026-08-23
AI Tool Finder
AI-powered search. Results may not be comprehensive.